

as of 30 JUNE 2025								
CT Tracking Number	Protocol Code/Title	Classification	Disease/Cancer Site	Key Inclusion Criteria	Contact Number/s	Institute / Department	Status	Site
SL-24319	International DP/AI Early Experience Program for HER2 - An international project investigating AI-assisted HER2 IHC assessment in breast cancer	-	Breast Cancer			Institute of Pathology	Approved and Ongoing	SLMC-GC
SL-24268	A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION-Lung15)/D516KC00001	Phase III	Metastatic Non-small Cell Lung Cancer	https://clinicaltrials.gov/study/NCT06417814?term=D516KC00001&rank=1	CP: +639569229948	Cancer Institute	-	SLMC-QC
SL-24186	117002- Validation of a prostaglandin-associated periorbitopathy (PAP) symptoms patient reported outcome measure (PROM) screening tool	-	Prostaglandin-associated periorbitopathy (PAP)			Eye Institute	Approved and Ongoing	SLMC- QC
SL-24184	D6402C00012 A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function/	-	Heart failure and Impaired Kidney	https://clinicaltrials.gov/study/NCT06307652?term=D6402C00012%20&rank=1	CP: +639077657031	Cardiac Arrhythmia Center	Approved and Ongoing	SLMC- QC
SL-24180	A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function/D6402C00012	-	Heart failure and Impaired Kidney	https://clinicaltrials.gov/study/NCT06307652?term=D6402C00012%20&rank=1	CP: +639178402810	Cardiac Arrhythmia Center	Recruiting	SLMC-QC
SL-24179	A Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapagliflozin, on the Risk of Heart Failure Events and Cardiovascular Death in Patients with Heart Failure and Impaired Kidney Function/D6402C00012	-	Heart failure and Impaired Kidney	https://clinicaltrials.gov/study/NCT06307652?term=D6402C00012%20&rank=1	CP: +639178019052	Cardiac Arrhythmia Center	Recruiting	SLMC-GC

SL-24178	D9673R00037 - iRetroBC-HER2L Study (GC) / A Multicenter, Retrospective, Noninterventional Study to Determine the Prevalence of HER2-low, Clinical Characteristics, Treatment Patterns, and Associated Outcomes in Patients Previously Identified With HER2 negative Locally-advanced or Metastatic Breast Cancer Who Progressed on Systemic Anticancer Therapy	Non interventional	Metastatic Breast Cancer	https://clinicaltrials.gov/study/NCT06131424?term=D9673R00037&rank=1#participation-criteria		Cancer Institute	New	SLMC Global City
SL-24177	An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician's Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer/MK-2870-010	-	Metastatic Breast Cancer	https://clinicaltrials.gov/study/NCT06312176?term=MK-2870-010&rank=1	CP: +639171796173	Cancer Institute	Approved and Ongoing	SLMC-QC
SL-24164	LG-VGCL002 / A Phase II, Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter Study to Evaluate the Immunogenicity and Safety of DTaP-HepB-IPV-Hib Hexavalent Vaccine LR20062 Versus Hexaxim Administered Intramuscularly in Healthy Infants as Primary Series At 2, 4, 6 Months of Age	Phase III	diphtheria, tetanus, poliovirus (Sabin Strain) types 1,2 and 3, Hep B and Hib antigens	https://clinicaltrials.gov/study/NCT06618196?term=LG-VGCL002&rank=1#participation-criteria	CP: +639178019052	Institute of Pediatrics and Child Care	New	SLMC Quezon City
SL-24155	Empagliflozin-CKD/Economic Evaluation of Empagliflozin for the Management of Chronic Kidney Disease (CKD) in the Philippines: A Costing, Cost-effectiveness Analysis and Budget Impact Analysis Protocol	Observational	Chronic Kidney Disease (CKD)		CP: +639338137890	Department of Medicine and Center for Renal Diseases	Data Collection	SLMC Quezon City
SL-24102	D6970C00008/A Double-Blind, Randomized, Placebo-Controlled, Multicentre Study Evaluating the Efficacy and Safety of Baxdrostat in Asian Participants with Uncontrolled Hypertension on Two or More Medications including Participants with Resistant Hypertension (BaxAsia)	Phase III	Uncontrolled Hypertension , Resistant Hypertension	https://clinicaltrials.gov/study/NCT06344104?term=D6970C00008&rank=1#participation-criteria	CP: +639178402810	Dr. HB Calleja Heart and Vascular Institute	New	SLMC Quezon City
SL-24006	V940-002 A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With Resected Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer/	Phase III	Non-small Cell Lung Cancer	https://clinicaltrials.gov/study/NCT06077760?cond=V940-002&rank=1		Cancer Institute	Recruiting	SLMC- QC

SL-23375	MK-6194-006 / A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-6194 in Adult Participants with Systemic Lupus Erythematosus	Phase 2a	Systemic Lupus Erythematosus	https://clinicaltrials.gov/study/NCT06161116?term=MK-6194-006&rank=1#participation-criteria	CP: +639171796173 CP: +639216880657 Fax +632-89076173	Department of Medicine	New	SLMC Quezon City
SL-23355	D7630C00001/A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)	Phase III	Metastatic Triple-negative Breast Cancer	https://clinicaltrials.gov/study/NCT06103864?term=TROPION-Breast05&rank=1#participation-criteria	CP: +639569229948 Office: +632-86617865	Cancer Institute	Active and recruiting	SLMC Quezon City
SL-23354	D8535C00001/A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (CAMBRIA-2)	Phase III	ER+/HER2- Early Breast Cancer	https://clinicaltrials.gov/study/NCT05952557?term=D8535C00001&rank=1#participation-criteria	CP: +639171796173 CP: +639216880657 Fax +632-89076173	Cancer Institute	Active and recruiting	SLMC Quezon City
SL-23351	TAS6417-301 (REZILIENT-3)/Randomized, Controlled, Open-label, Phase 3, Global MultiCenter Trial to Assess the Efficacy and Safety of Ziplertinib plus Chemotherapy versus Chemotherapy alone, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations	Phase III	Metastatic Nonsquamous Non-Small Cell Lung Cancer	https://clinicaltrials.gov/study/NCT05973773?term=TAS6417-301&rank=1#participation-criteria	CP: +639356002648 Office: +632-86617865	Cancer Institute	Active and recruiting	SLMC Quezon City
SL-23337	MK-2870-004-3601/A Randomized, Open-label, Phase 3 of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other Genomic Alterations	Phase III	Metastatic Nonsquamous Non-small Cell Lung Cancer	https://clinicaltrials.gov/study/NCT06074588?term=MK-2870%20vs%20Chemotherapy%20(Docetaxel%20or%20Pemetrexed)%20&rank=1#participation-criteria	CP: +639610567340 Office: +632-86617865	Cancer Institute	Active and recruiting	SLMC Quezon City

SL-23273	SB27-3004 /A Phase III Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity between SB27 (proposed pembrolizumab biosimilar) and Keytruda in Subjects with Metastatic Non-squamous Non-small Cell Lung Cancer	Phase III	Metastatic Non-squamous Non-small Cell Lung Cancer	https://clinicaltrials.gov/study/NCT06348199?term=SB27-3004&rank=1#participation-criteria	CP: +639234600376 Office: +632-86617865	Cancer Institute	Active and recruiting	SLMC Quezon City
SL-23242	VT-001-0050 / A Phase 2b/3, Multi-part, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ataricept in Subjects with IgA Nephropathy (IgAN)	Phase 2B/3	IgA Nephropathy (IgAN)	https://clinicaltrials.gov/study/NCT04716231?term=VT-001-0050&rank=1#participation-criteria	CP: +639085378888	Department of Medicine	Active and recruiting	SLMC Quezon City
SL-23208	D5087C00001/A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)	Phase III	Locally Advanced or Metastatic Non-Small Cell Lung Cancer	https://clinicaltrials.gov/study/NCT05261399?term=D5087C00001&rank=1#participation-criteria	CP: +639171796173 Fax +632-89076173	Cancer Institute	Active and recruiting	SLMC Quezon City
SL-23187	ESK-001-010/A Phase 2, Multicenter, Multinational, Randomized, double-blind, Placebo-controlled Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Dose Levels of ESK-001 in Adult Patients with Systemic Lupus Erythematosus	Phase III	Systemic Lupus Erythematosus	https://clinicaltrials.gov/study/NCT05966480?term=ESK-001-010&rank=1#participation-criteria	CP: +639171796173 Fax +632-89076173	Department of Medicine	Active and recruiting	SLMC Quezon City
SL-23161	MX39897 / A Registry to Collect Characteristics and Outcomes from Patients with Solid Tumors Profiled with a Next Generation Sequencing (NGS) Test (WAYFIND-R)	Registry	Solid Tumors Profiled with a Next Generation Sequencing (NGS) Test	https://clinicaltrials.gov/study/NCT04529122?term=MX39897&rank=1#participation-criteria	CP: +639064309933	Cancer Institute	Active and recruiting	SLMC Quezon City
SL-23148	R3918-PNH-2021/A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who are Complement Inhibitor Treatment-Naive or Have Not Recently Complement Inhibitor Therapy	Phase III	Paroxysmal Nocturnal Hemoglobinuria	https://clinicaltrials.gov/study/NCT05133531?term=R3918-PNH-2021&rank=2#participation-criteria	CP: +639171796173 Fax +632-89076173	Cancer Institute	Active and recruiting	SLMC Quezon City

SL-23147	D8531C00002/A Phase III, Open-Label, Randomised Study to assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degradar) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence (CAMBRIA-1)	Phase III	ER+/HER2- Early Breast Cancer	https://clinicaltrials.gov/study/NCT05774951?term=D8531C00002&rank=1#participation-criteria	CP: +639171796173 CP: +639216880657 Fax +632-89076173	Cancer Institute	New	SLMC Quezon City
SL-23141	CKJX839D12302 /A randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT)	Phase III	Cardiovascular disease	https://clinicaltrials.gov/study/NCT05739383?term=CKJX839D12302&rank=1#participation-criteria	CP: +639178402810	Dr. HB Calleja Heart and Vascular Institute	Active and recruiting	SLMC Quezon City
SL-23132	KZR-616-202 /Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis	Phase 2B	Lupus Nephritis	https://clinicaltrials.gov/study/NCT05781750?term=KZR-616-202&rank=1#participation-criteria	CP: +639171796173 CP: +639216880657 Fax +632-89076173	Department of Medicine	Active and recruiting	SLMC Quezon City
SL-23131	KZR-616-202/Phase 2b, Randomized, Controlled Double-blind, Multicenter Study Comparing the Efficacy and Safety of Zetomipzomib (KZR-616) 30 mg or 60 mg with Placebo in Patients with Active Lupus Nephritis	Phase 2B	Lupus Nephritis	https://clinicaltrials.gov/study/NCT05781750?term=KZR-616-202&rank=1#participation-criteria	CP: +639171796173 Fax +632-89076173	Department of Medicine	Active and recruiting	SLMC Quezon City
SL-23125	D910VC00001/A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)	Phase III	Locoregional Hepatocellular Carcinoma	https://clinicaltrials.gov/study/NCT05301842?term=EMERALD-3&rank=1#participation-criteria	CP: +639610567340 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City
SL-23092	ISU303-003 / A Phase 3, Randomized, Double-blinded, Active-controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Fabagal® (agalsidase beta) in Patients with Fabry disease	Phase III	Fabry disease	https://clinicaltrials.gov/study/NCT06081062?term=ISU303-003&rank=1#participation-criteria	CP: +639178019052	Dr. Calleja Heart and Vascular Institute	Active and recruiting	SLMC Quezon City

SL-23091	70033093STR3001 / A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor Xa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack (Librexia STR)	Phase III	Acute Ischemic Stroke or High-Risk Transient Ischemic Attack	https://clinicaltrials.gov/study/NCT05702034?term=70033093STR3001&rank=1#participation-criteria	CP: +639325441733	Institute for Neurosciences	New	SLMC Quezon City
SL-23080	SPH-PMS-01 / Post-marketing observational study on safety and efficacy of Omidienepag isopropyl (EYEBLIS) ophthalmic solution in Filipino patients with glaucoma or ocular hypertension	PMS	Glaucoma or ocular hypertension			Eye Institute	Active and recruiting	SLMC Quezon City
SL-23050	CID-2020-NUT-001 / The effect of Silybin + Phosphatidylcholine + Multivitamins + Zinc on the Non-invasive Parameters of Hepatic Injury in Adults with Metabolic Associated Fatty Liver Disease: a Double-blind Randomized Placebo-controlled Trial	Phase III	Fatty Liver Disease		CP: +639189271401	Liver and Transplant Center	Active and recruiting	SLMC Quezon City
SL-23031	70033093AFL3002 / A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor Xa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation (Librexia-AF)	Phase III	Atrial Fibrillation	https://clinicaltrials.gov/study/NCT05757869?term=70033093AFL3002&rank=1#participation-criteria	CP: +639178019052	Heart Institute-Global City	New	SLMC Global City
SL-23018	ID-064A302/A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy	Phase III	Systemic Lupus Erythematosus	https://clinicaltrials.gov/study/NCT05672576?term=ID-064A302&rank=1#participation-criteria	CP: +639216880657 Fax: +632-89076173	Department of Medicine	Active and recruiting	SLMC Quezon City
SL-23017	CNT01959PSA400/A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naïve Participants with Active Psoriatic Arthritis Axial Disease (STAR Study)	Phase IV	Psoriatic Arthritis Axial Disease (STAR Study)	https://clinicaltrials.gov/study/NCT04929210?term=Evaluating%20the%20Efficacy%20and%20Safety%20of%20Guselkumab%20Administered%20Subcutaneously%20in%20Bio-naïve%20Participants%20&rank=1#participation-criteria	CP: +639171796173 CP: +639216880657 Fax +632-89076173	Department of Medicine	Active and recruiting	SLMC Quezon City
SL-23016	GLPG0634-CL-336/A Phase 3 randomized, placebo-controlled, double-blind, parallel-group program to evaluate efficacy and safety of filgotinib in adult subjects with active axial spondyloarthritis	Phase III	axial spondyloarthritis	https://clinicaltrials.gov/study/NCT05785611?term=GLPG0634-CL-336&rank=1#participation-criteria	CP: +639171796173 Fax +632-89076173	Department of Medicine	Active and recruiting	SLMC Quezon City

SL-22300	CVAY736Q12301 / A phase 3 randomized, double-blind study of ivalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response relapsed after first line steroid treatment (VAYHIT2)	Phase III	primary immune thrombocytopenia (ITP)	https://clinicaltrials.gov/study/NCT05653219?term=CVAY736Q12301&rank=1#participation-criteria	CP: +639189271401	Cancer Institute	Active and recruiting	SLMC Quezon City
SL-22247	230LE301/A 2-Part Seamless Part A (Phase 2) /Part B (Phase 3) Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety BII059 in Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus with or without Systemic Manifestations and Refractory and/or Intolerant to Antimalarial Therapy (AMETHYST)	Phase II/III	Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythematosus	https://clinicaltrials.gov/study/NCT05531565?term=230LE301&rank=2#participation-criteria	CP: +639171796173 Fax +632-89076173	Department of Medicine	Active and recruiting	SLMC Quezon City
SL-22246	R3918-PNH-2050/An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (ACCESS-EXTENSION)	Phase III	Paroxysmal Nocturnal Hemoglobinuria	https://clinicaltrials.gov/study/NCT05744921?term=R3918-PNH-2050&rank=1#participation-criteria	CP: +639171796173 Fax +632-89076173	Cancer Institute	Active and recruiting	SLMC Quezon City
SL-22238	MK-3475-D46 /An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-lineTreatment in Participants With PD L1 TPS Greater than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)	Phase III	Metastatic Non-small Cell Lung Cancer	https://clinicaltrials.gov/study/NCT05609968?term=MK-3475-D46&rank=1#participation-criteria	CP: +639234600376 Office: +632-86617865	Cancer Institute	Active and recruiting	SLMC Quezon City
SL-22190	CLNP023K12201 / An adaptive, randomized, double-blind, dose exploration, parallel group, placebocontrolled, multicenter phase 2 trial to evaluate the efficacy, safety and tolerability of LNP023 in combination with standard-of-care with and without oral corticosteroids in adult patients with active lupus nephritis Class III-IV, +/-V	Phase II	Lupus nephritis Class III-IV, +/-V	https://clinicaltrials.gov/study/NCT05268289?term=CLNP023K12201%20&rank=1#participation-criteria	CP: +639216880657 Fax: +632-89076173	Department of Medicine	Active and recruiting	SLMC Quezon City
SL-22181	1366-0031/ A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis (VITALISScE™)	Phase II	Diffuse cutaneous systemic sclerosis	https://clinicaltrials.gov/study/NCT05559580?term=1366-0031&rank=1#participation-criteria	CP: +639171796173 CP: +639216880657 Fax +632-89076173	Department of Medicine	Active and recruiting	SLMC Quezon City

SL-22167	D926PC00001/A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02)	Phase III	Metastatic Triple-negative Breast Cancer	https://clinicaltrials.gov/study/NCT05374512?term=TROPION-Breast02&rank=1#participation-criteria	CP: +639610567340 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City
SL-22143	417-201-00012/A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term Safety, Tolerability, and Efficacy of Sipeprelimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy (OTIG 203)	Phase II/III	Immunoglobulin A Nephropathy	https://clinicaltrials.gov/study/NCT05248659?term=417-201-00012&rank=1#participation-criteria	CP: +639338137890	Department of Medicine	Active not recruiting	SLMC Quezon City
SL-22083	417-201-00007 / A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sipeprelimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy	Phase III	Immunoglobulin A Nephropathy	https://clinicaltrials.gov/study/NCT05248646?term=417-201-00007&rank=1#participation-criteria	CP: +639338137890	Department of Medicine	Active and recruiting	SLMC Quezon City
SL-22045	D9075C00001/A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab(AB154)in Participants with Locally Advanced(Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8)	Phase III	Locally Advanced(Stage III), Unresectable Non-small Cell Lung Cancer	https://clinicaltrials.gov/study/NCT05211895?term=D9075C00001&rank=1#participation-criteria	CP: +639171796173 Fax +632-89076173	Cancer Institute	Active and recruiting	SLMC Quezon City
SL-21373	BETTER Study / Using erdosteine to improve outcomes of children with bronchiectasis - a double-blind, randomised controlled trial or abbreviated title BronchiEcstasis Trial Testing Erdosteine (BETTER)	ARO	Bronchiectasis		CP: +639959512764	Institute of Pediatric and Child Care	Active and recruiting	SLMC Quezon City
SL-21329	CKJX839B12302/A randomized, double-blind, placebo-controlled, multicenter trial, assessing the impact of inclisiran on major adverse cardiovascular events in participants with established cardiovascular disease (VICTORION-2 PREVENT)	Phase III	Cardiovascular disease	https://clinicaltrials.gov/study/NCT05030428?term=CKJX839B12302&rank=1#participation-criteria	CP: +639178402810	Dr. HB Calleja Heart and Vascular Institute	Active not recruiting	SLMC Quezon City
SL-21326	NANORAY-312/A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigator's Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma	Phase III	Locally Advanced Head & Neck Squamous Cell Carcinoma	https://clinicaltrials.gov/study/NCT04892173?term=nANORAY-312%2F&rank=1#participation-criteria	CP: +639171796173 Fax +632-89076173	Cancer Institute	Active and recruiting	SLMC Quezon City

SL-21271	D967RC00001/A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)	Phase III	Breast Cancer	https://clinicaltrials.gov/study/NCT05113251?term=DESTINY-Breast11&rank=1#participation-criteria	CP: +639610567340 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City
SL-21248	230LE303/A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants with Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care (TOPAZ)	Phase III	Systemic Lupus Erythematosus	https://clinicaltrials.gov/study/NCT04895241?term=Efficacy%20and%20Safety%20of%20BIIB059%20in%20Adult%20Participants%20with%20Active%20Systemic%20Lupus%20Erythematosus&rank=2#participation-criteria	CP: +639171796173 Fax +632-89076173	Department of Medicine	Active and recruiting	SLMC Quezon City
SL-21227	MASTERKEY-ASIA/Marker Assisted Selective Therapy in Rare cancers: Knowledge database Establishing registry Asia Protocol: A Prospective clinical registry study of genetic profiling and targeted therapies in patients with rare cancers in ASIA	Registry	Rare cancers in ASIA	https://clinicaltrials.gov/study/NCT05217407?term=Marker%20Assisted%20Selective%20Therapy%20in%20Rare%20cancers:%20&rank=1#participation-criteria	CP: +639356002648 CP: +639663079516	Cancer Institute	Data Collection	SLMC Quezon City
SL-21184	GO42784/A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer	Phase III	Breast Cancer	https://clinicaltrials.gov/study/NCT04961996?term=GO42784&rank=1#participation-criteria	CP: +639610567340 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City
SL-21142	D3468C00003/A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants with Active Systemic Lupus Erythematosus (AZALEA)	Phase III	Systemic Lupus Erythematosus	https://clinicaltrials.gov/study/NCT04931563?term=D3468C00003&rank=1#participation-criteria	CP: +639171796173 Fax +632-89076173	Department of Medicine	Active not recruiting	SLMC Quezon City
SL-21124	D967YC00001/A Phase 1b Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)	Phase Ib	Metastatic Non-squamous Non-small Cell Lung Cancer	https://clinicaltrials.gov/study/NCT04686305?term=DESTINY-Lung03&rank=1#participation-criteria	CP: +639234600376 Office: +632-86617865	Cancer Institute	Active and recruiting	SLMC Quezon City
SL-21087	D967UC00001/Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY Breast09)	Phase III	First-line Metastatic Breast Cancer	https://clinicaltrials.gov/study/NCT04784715?term=DESTINY%20Breast09&rank=1#participation-criteria	CP: +639234600376 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City

SL-21067	BO42162/ A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Crovalimab Versus Eculizumab In Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors (COMMODORE)	Phase III	Paroxysmal Nocturnal Hemoglobinuria (PNH)	https://clinicaltrials.gov/study/NCT04434092?term=BO42162&rank=1#participation-criteria	CP: +639189271401	Cancer Institute	Active not recruiting	SLMC Quezon City
SL-21025	MO42319 KATE 3 / A randomized, multicenter, double-blind, placebo-controlled Phase III study of the efficacy and safety of trastuzumab emtansine in combination with atezolizumab or placebo in patients with HER2-positive and PD-L1-positive locally advanced or metastatic breast cancer who have received prior trastuzumab- (+/-pertuzumab) and taxane-based therapy	Phase III	Metastatic breast cancer	https://clinicaltrials.gov/study/NCT04740918?term=MO42319&rank=1#participation-criteria	CP: +639610567340 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City
SL-21011	INTERASPIRE Study /A Survey of Cardiovascular Disease Prevention, Diabetes and Chronic Kidney Disease in Partnership with the World Heart Federation, European Society of Cardiology, Inter-American Society of Cardiology, Pan-African Society of Cardiology and Asian Pacific Society of Cardiology	Survey	Cardiovascular Disease , Diabetes and Chronic Kidney Disease		CP: +639178402810	Dr. HB Calleja Vascular and Heart Institute	Active not recruiting	SLMC Quezon City
SL-20367	MOR208C310/A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL)	Phase III	Diffuse large B-cell lymphoma (DLBCL)	https://clinicaltrials.gov/study/NCT04824092?term=MOR208C310&rank=1#participation-criteria	CP: +639189271401 CP: +639171796173 Fax +632-89076173	Cancer Institute	Active not recruiting	SLMC Quezon City
SL-20235	D361BC0001/A Phase III Double-Blind Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPitello-281)	Phase III	De Novo Metastatic Hormone-Sensitive Prostate Cancer	https://clinicaltrials.gov/study/NCT04493853?term=CAPitello-281&rank=1#participation-criteria	CP: +639610567340 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City
SL-20170	INCMGA0012-304/A Randomized, Double-blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA0012 in First-Line Metastatic Squamous and NonSquamous Non-Small Cell Lung Cancer (POD1UM-304)	Phase III	First-line Metastatic Squamous and NonSquamous Non-Small Cell Lung Cancer	https://clinicaltrials.gov/study/NCT04205812?term=A%20Randomized.%20Double-blind.%20Phase%203%20Study%20of%20Platinum-Based%20Chemotherapy%20With%20or%20Without%20INCMGA0012%20&rank=1#participation-criteria	CP: +639234600376 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City

SL-20132	MK3475 PN587/A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial (KEYNOTE-587)	Phase III	Advanced tumors in a Pembrolizumab Trial	https://clinicaltrials.gov/study/NCT03486873?term=(KEYNOTE-587)&rank=1#participation-criteria	CP: +639569229948 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City
SL-20130	D5169C00001/A Phase III, Open-label, Randomized Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA 2)	Phase III	Metastatic Non-small Cell Lung Cancer	https://clinicaltrials.gov/study/NCT04035486?term=A%20Phase%20III,%20Open-label,%20Randomized%20Study%20of%20Osimertinib%20with%20or%20without%20Platinum%20Plus%20Pemetrexed%20Chemotherapy&rank=1#participation-criteria	CP: +639610567340 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City
SL-20060	CAIN457P12301/A Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase III Multicenter Study of Intravenous Secukinumab to Compare Efficacy at 16 weeks with Placebo and to Assess Safety and Tolerability up to 52 weeks in Subjects with Active Ankylosing Spondylitis or non-radiographic axial SpondyloArthritis	Phase III	Ankylosing Spondylitis or non-radiographic axial SpondyloArthritis	https://clinicaltrials.gov/study/NCT04156620?term=CAIN457P12301&rank=1#participation-criteria	CP: +639171796173 Fax +632-89076173	Department of Medicine	Active not recruiting	SLMC Quezon City
SL-20059	CHS1221 (cessa) / A Three-Arm, Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Safety and Efficacy of Once-Daily and Twice-Daily Dosing of a Novel Hydrocortisone Acetate 90mg Suppository Formulation Administered with the Sephure® Suppository Applicator in Subjects with Ulcerative Colitis of the Rectum	Phase III	Ulcerative Colitis of the Rectum	https://clinicaltrials.gov/study/NCT04469686?term=CHS1221%20&rank=1#participation-criteria	CP: +639338137890	Institute of Digestive and Liver Diseases	Active and recruiting	SLMC Quezon City
SL-20058	D822BC00001/A Randomized, Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Acalabrutinib versus Chlorambucil plus Rituximab in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (ACERTA)	Phase III	Chronic Lymphocytic Leukemia	https://clinicaltrials.gov/study/NCT04075292?limit=100&term=D822BC00001&rank=1#participation-criteria	CP: +639189271401	Cancer Institute	Active not recruiting	SLMC Quezon City
SL-20013	D3614C00001/A Phase III Double-Blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advance (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC) (CAPitello-290)	Phase III	Metastatic Triple-Negative Breast Cancer	https://clinicaltrials.gov/study/NCT03997123?term=A%20Phase%20III%20Double-Blind%20Randomised%20Study%20Assessing%20the%20Efficacy%20and%20Safety%20of%20Capivasertib%20%2B%20Paclitaxel%20&rank=1#participation-criteria	CP: +639234600376 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City

SL-19287	MK-3475-975/A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE-975)	Phase III	Esophageal Carcinoma	https://clinicaltrials.gov/study/NCT04210115?term=A%20Randomized,%20Double-blind,%20Placebo-controlled%20Phase%203%20Trial%20of%20Pembrolizumab%20(MK-3475)%20&rank=2#participation-criteria	CP: +639569229948 Office: +632-86617865	Cancer Institute	Active not recruiting	SLMC Quezon City
SL- 23090	70033093ACS3003 "A Phase 3, Randomized, Double-blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome (Librexia – ACS)/70033093ACS3003"	Phase III	Acute Coronary Syndrome	https://clinicaltrials.gov/study/NCT05754957?term=70033093ACS3003%20&rank=1	CP: +639178019052	Dr. HB Calleja Heart and Vascular Institute	Recruiting	SLMC- QC
CT-19288	APL2-307/An Open-Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long-Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase III	Paroxysmal Nocturnal Hemoglobinuria (PNH)	https://clinicaltrials.gov/study/NCT03531255?term=APL2-307&rank=1#participation-criteria	CP: +639189271401	Cancer Institute	Active not recruiting	SLMC Quezon City
CT-19022	EVER-AT-0717 / "Cerebrolysin REGistry Study in Stroke." A registry study to observe clinical practices, safety and efficiency of routine use of Cerebrolysin in the treatment of patients with moderate to severe neurological deficits after acute ischemic stroke	Registry	Acute ischemic stroke	https://clinicaltrials.gov/study/NCT03480698?term=EVER-AT-0717&rank=1#participation-criteria		Institute for Neurosciences	Data Collection	SLMC Quezon City
CT-17049	ATLAS 2022 / Antimicrobial Testing Leadership And Surveillance (Former AstraZeneca Global Surveillance Study 2017)	Observational	Antimicrobial Testing Leadership And Surveillance (Former AstraZeneca Global Surveillance Study 2017)		CP: +639175444737	Institute of Pathology	Active and recruiting	SLMC Quezon City
CT-17048	SMART 2022 / Study for Monitoring Antimicrobial Resistance Trends	Observational	Study for Monitoring Antimicrobial Resistance Trends		CP: +639175444737	Institute of Pathology	Active and recruiting	SLMC Quezon City
CT-13014	HEALER Study AD_Aβ+ / Safety of Plasma Aβ1-42 and Aβ1-40 Reduction with H.E.A.L.E.R (Haemoadsorption for Extra Corporeal Amyloid_B Level Expedited Reduction) using Betaclear βicarb 1000 in Healthy Elderly Individuals	Phase I	Safety of Plasma Aβ1-42 and Aβ1-40 Reduction with H.E.A.L.E.R (Haemoadsorption for Extra Corporeal Amyloid_B Level Expedited Reduction) using Betaclear βicarb 1000 in Healthy Elderly Individuals			Department of Geriatrics	Active not recruiting	SLMC Quezon City
CT-13006	BAY 59-7939/15786 COMPASS Study / A Randomized, Controlled Trial Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients with Coronary or Peripheral Artery Disease (COMPASS-Cardiovascular Outcomes for People using Anticoagulation Strategies)	Phase III	Coronary or Peripheral Artery Disease	https://clinicaltrials.gov/study/NCT01776424?term=compass&rank=62#participation-criteria	CP: +639178019052	Dr. HB Calleja Heart and Vascular Institue	Active not recruiting	SLMC Quezon City